GSK Plc reported a double-digit increase in sales for the third quarter and a pipeline of 65 potential vaccines and medicines as it transitioned to a new structure. On 18 July, it spun off its consumer healthcare business, Haleon, into an independently listed company. The new GSK retains a minority stake in the business, but going forward it will focus on specialty medicines, vaccines and new technologies.
